Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial
Esmé Eggink,Melanie Hafdi,Marieke P Hoevenaar-Blom,Manshu Song,Sandrine Andrieu,Linda E Barnes,Cindy Birck,Rachael L Brooks,Nicola Coley,Elizabeth Ford,Jean Georges,Abraham van der Groep,Willem A van Gool,Ron Handels,Haifeng Hou,Dong Li,Hongmei Liu,Jihui Lyu,Harm van Marwijk,Mark van der Meijden,Yixuan Niu,Shanu Sadhwani,Wenzhi Wang,Youxin Wang,Anders Wimo,Xiaoyan Ye,Yueyi Yu,Qiang Zeng,Wei Zhang,Wei Wang,Carol Brayne,Eric P Moll van Charante,Edo Richard
DOI: https://doi.org/10.1136/bmjopen-2021-049762
IF: 3.006
2021-06-01
BMJ Open
Abstract:Introduction Profiles of high risk for future dementia are well understood and are likely to concern mostly those in low-income and middle-income countries and people at greater disadvantage in high-income countries. Approximately 30%–40% of dementia cases have been estimated to be attributed to modifiable risk factors, including hypertension, smoking and sedentary lifestyle. Tailored interventions targeting these risk factors can potentially prevent or delay the onset of dementia. Mobile health (mHealth) improves accessibility of such prevention strategies in hard-to-reach populations while at the same time tailoring such approaches. In the current study, we will investigate the effectiveness and implementation of a coach-supported mHealth intervention, targeting dementia risk factors, to reduce dementia risk. Methods and analysis The prevention of dementia using mobile phone applications (PRODEMOS) randomised controlled trial will follow an effectiveness–implementation hybrid design, taking place in the UK and China. People are eligible if they are 55–75 years old, of low socioeconomic status (UK) or from the general population (China); have ≥2 dementia risk factors; and own a smartphone. 2400 participants will be randomised to either a coach-supported, interactive mHealth platform, facilitating self-management of dementia risk factors, or a static control platform. The intervention and follow-up period will be 18 months. The primary effectiveness outcome is change in the previously validated Cardiovascular Risk Factors, Ageing and Incidence of Dementia dementia risk score. The main secondary outcomes include improvement of individual risk factors and cost-effectiveness. Implementation outcomes include acceptability, adoption, feasibility and sustainability of the intervention. Ethics and dissemination The PRODEMOS trial is sponsored in the UK by the University of Cambridge and is granted ethical approval by the London—Brighton and Sussex Research Ethics Committee (reference: 20/LO/01440). In China, the trial is approved by the medical ethics committees of Capital Medical University, Beijing Tiantan Hospital, Beijing Geriatric Hospital, Chinese People’s Liberation Army General Hospital, Taishan Medical University and Xuanwu Hospital. Results will be published in a peer-reviewed journal. Trial registration number ISRCTN15986016 .
medicine, general & internal